RxDoctor Payments Data

Edwin McDonald

Gastroenterology · Chicago, ILNPI 1831346774

Payments from drug & device makers

$55,310in general payments, 2019–2025

Across 40 payments — averaging $1382.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius Kabi USA, LLC$30K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$9K
  • Ironwood Pharmaceuticals, Inc$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$6K
  • AbbVie$3K
  • Zimvie Inc.$812
  • plus $496 from 6 others
$7,600in research payments, 2019–2025

Across 2 payments — averaging $3800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$8K

What the payments were for

  • Consulting fees$13,48953%
  • Speaking & faculty fees$7,60030%
  • Travel & lodging$3,33113%
  • Food & beverage$8904%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,310 in reported general payments places this provider in the 85th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$69,617
Medicare patients
286
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide44$2,050,551
OzempicSemaglutide83$117,422
LinzessLinaclotide52$44,419
CreonLipase/Protease/Amylase22$28,562
MounjaroTirzepatide13$18,873
Octreotide Acetate32$6,460
Esomeprazole Magnesium39$4,719
Famotidine40$719
Pantoprazole Sodium35$521
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$458
Omeprazole36$379
Dicyclomine Hcl12$349
Sodium Chloride0.9 % Sodium Chloride15$335
Ondansetron OdtOndansetron16$219
Metformin Hcl32$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$5,578$2,050,55144 claims
AbbVieLinzess, Creon$3,325$72,98174 claims
Fresenius Kabi USA, LLCSodium Chloride$30,000$33515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →